From Academia to Startup: Five Things Researchers Forget to Think About When Building in Life Sciences

A few weeks ago I sat down with two researchers who are in the early stages of turning their academic work on neurodegenerative disease diagnostics into a company. Both are postdoctoral scientists at a German university. The science is solid. The clinical problem they are addressing is real and underserved. And yet, like most academic founders I meet, they had a significant blind spot: the connective tissue between the lab and the market.

What followed was not a consulting session. It was a conversation. I shared what I knew, pointed to resources I had personally used or encountered, and we figured out together where the gaps were. This kind of exchange is exactly what I built Stumpf Co-Lab around. Here is what came up, and why it matters for anyone in a comparable position.

Free IP Counsel Exists — If You Know Where to Look

Intellectual property is one of the most consequential and most neglected topics for early-stage life science ventures. Patent strategy is expensive to get wrong and expensive to get right, which leads many academic founders to defer the conversation entirely until it is too late.

The timing problem is structural. Academic researchers are trained to publish, and publication creates prior art that can destroy patentability if a filing has not been made first. This is not hypothetical; it is a pattern I have seen repeatedly. The pressure to publish for career reasons and the need to protect IP for commercial reasons are in direct tension, and resolving that tension requires a deliberate strategy, not a default.

What few people know is that accessible resources exist specifically for this stage. In the Frankfurt Rhine-Main area, specialised IP lawyers from established patent firms hold regular sessions at startup-focused hubs, specifically oriented toward early-stage founders. For a team that is pre-revenue and pre-seed, having access to qualified patent counsel before committing to a filing strategy can be the difference between building protectable IP and building nothing that sticks. These sessions are free. They are not widely advertised. I connected the team directly to one such resource, because that kind of network knowledge does not come from a Google search. It comes from having been embedded in the ecosystem long enough to know who shows up and what they are willing to discuss.

Conference Presence Is a Strategic Decision, Not a Calendar Event

The two researchers mentioned BIO Europe as a conference they had been tracking for years without attending. This is more common than it should be. The barrier is usually cost, which is real, but the more correctable problem is that most people who do attend underinvest in preparation and therefore underperform on outcomes.

BIO Europe is one of the few partnering-focused events in European biopharma where the primary format is pre-arranged one-on-one meetings, not lectures. The quality of your outcomes is almost entirely determined by how well your company profile is written before you arrive, because the matching algorithm uses that profile to suggest counterparts. A generic profile produces generic matches. A sharply positioned profile — one that communicates your technology differentiator, your stage, and the specific type of partner you are looking for — can produce ten to fifteen genuinely relevant meetings across two days.

Getting that profile right requires thinking clearly about what you are actually offering and what you actually need from a partnership, which sounds obvious but is harder than it looks when you are still close to the science and have not yet forced yourself to translate it into commercial language. The framing that works for a grant application does not work for a partnering platform. The framing that excites a fellow researcher will not necessarily excite a business development director at a mid-sized pharma company. These are different communication tasks and they require deliberate preparation.

I attended multiple BIO Europe editions and supported Senostic's representation at BIO Europe 2024, where we ran 28 international partnering meetings over two days. The profile work that preceded that result was not an afterthought. For the team I spoke with, BIO Europe 2026 in Cologne is a realistic and proximate first opportunity. I offered to support them with profile setup when they are ready.

Reimbursement Logic Is Part of Your Market Access Thesis — Not an Afterthought

For any diagnostic venture targeting clinical application in Germany, understanding how the KBV billing framework currently codes and compensates comparable procedures gives you an early signal about your pricing corridor and addressable market ceiling. I pointed the team to the relevant public resource and flagged it as something worth mapping before, not after, the product design is locked.

Clinical Guidelines Tell You What the Standard of Care Currently Is Not

As part of the conversation, I shared a recently published clinical guideline for a rare neurodegenerative disease with significant diagnostic challenges — an area adjacent to work my former colleagues at Senostic had been involved with. The methodological point is transferable across indications: clinical guidelines are public documents that explicitly describe what diagnostic options currently exist, where evidence is lacking, and what gaps the clinical community has formally acknowledged. For a team developing diagnostic tools in the neurodegeneration space, this is primary source material for articulating the unmet need. Reading them is not optional if you want to be credible in front of clinical partners, investors, or regulatory bodies.

What This Kind of Conversation Is Actually For

None of what I described above required a formal engagement. It required being in the room, having the network, and being willing to connect dots rather than just describe them. The feedback I received afterward was that the session was genuinely useful in a practical way — not because I had answers to all their questions, but because I helped them see which questions they had not yet asked.

If you are building something in life science and you keep finding yourself at the boundary of your knowledge, that is not a sign that you are not ready. It is a sign that you need someone who has navigated that boundary before. That is what I am here for.

---

Reach me at daniel@stumpf-colab.de or book a first call directly via the website.